The Centre informed the Supreme Court in an affidavit that a new Covid-19 vaccine would be available soon for adolescents (12-18 years) from

It also said that 1.35 billion doses would be needed to vaccinate the adult population August onwards, and it expects availability of the same. This is a downward revision of the earlier estimate of 2.1 billion doses that the Centre had indicated it expects between August and December.




“It is submitted that Zydus Cadila, which is developing DNA vaccines, has concluded its clinical trial for those between the age group of 12 to 18 years and subject to the statutory permissions, the same may be available in near future for children of the age group of 12 to 18 years,” the Centre said in an affidavit to the top court.

A source in informed that the company plan to submit a formal application for approval of its vaccine soon.

1.35 bn doses between August and December

In the affidavit, the Centre said 1.86-1.88 billion doses are needed to vaccinate the adult population of 930-940 million.

Of these, 516 million doses will be made available by July 31, leaving a requirement of approximately 1.35 billion doses to complete the vaccination to the eligible population.

“It is submitted that this figure of 186.6 crore (1.87 billion) does not include other vaccines which are at various stages of development as on date within the country and may come and become available,” it said.

The Centre said that 346 million doses of Covid-19 vaccines have been procured so far. Of these, 266 million doses are of Covishield, and 80 million doses are of Covaxin.

Additionally, another 10 million doses have come from Covax, taking the total availability to 356 million doses. Apart from this, the Centre said it expects around 160 million doses between May and July.

The Government of India is making attempts to procure vaccines made outside India such as Pfizer, Johnson & Johnson, and Moderna.

Out of the 1.35 billion doses, 500 million doses will be of Covishield, and 400 million doses of Covaxin. The government expects 100 mn doses of Russian made Sputnik-V. Another 300 million will come from Biological E subunit vaccine, and 50 mn doses from

As on May 13, the MoHFW had estimated 750 mn doses of Covishield, 550 million doses of Covaxin, 156 million doses of Sputnik V, apart from 200 mn doses of Novavax vaccine (made here by Serum Institute) and 100 million doses of the nasal vaccine from Bharat Biotech, 60 million doses of Gennova’s mRNA vaccine and 50 mn doses of DNA-plasmid vaccine of Zydus.

Now Novavax, Gennova mRNA and Bharat Biotech’s nasal vaccines have been scrapped off the list and availability of doses from SII and Bharat Biotech for Covishield and Covaxin have been revised downwards.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor





Source link